In the past week, SWTX stock has gone down by -9.78%, with a monthly decline of -4.43% and a quarterly plunge of -5.56%. The volatility ratio for the week is 7.44%, and the volatility levels for the last 30 days are 6.12% for SpringWorks Therapeutics Inc The simple moving average for the last 20 days is -4.34% for SWTX’s stock, with a simple moving average of 20.81% for the last 200 days.
Is It Worth Investing in SpringWorks Therapeutics Inc (NASDAQ: SWTX) Right Now?
The 36-month beta value for SWTX is also noteworthy at 0.83. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for SWTX is 63.05M, and at present, short sellers hold a 16.72% of that float. The average trading volume of SWTX on May 09, 2024 was 1.15M shares.
SWTX) stock’s latest price update
The stock price of SpringWorks Therapeutics Inc (NASDAQ: SWTX) has dropped by -7.63 compared to previous close of 45.75. Despite this, the company has seen a fall of -9.78% in its stock price over the last five trading days. Seeking Alpha reported 2024-05-05 that Start Time: 08:30 January 1, 0000 9:06 AM ET SpringWorks Therapeutics, Inc. (NASDAQ:SWTX ) Q1 2024 Earnings Conference Call May 02, 2024, 08:30 AM ET Company Participants Saqib Islam – CEO Francis Perier – CFO Bhavesh Ashar – Chief Commercial Officer Jim Cassidy – CMO Samantha Sandler – Senior Director of IR Conference Call Participants Anupam Rama – JPMorgan Yaron Werber – TD Cowen Corinne Johnson – Goldman Sachs Peter Lawson – Barclays Alec Stranahan – Bank of America Michael Schmidt – Guggenheim Operator Good morning. My name is Tawanda, and I will be your conference operator today.
Analysts’ Opinion of SWTX
Many brokerage firms have already submitted their reports for SWTX stocks, with Guggenheim repeating the rating for SWTX by listing it as a “Buy.” The predicted price for SWTX in the upcoming period, according to Guggenheim is $75 based on the research report published on February 05, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see SWTX reach a price target of $45. The rating they have provided for SWTX stocks is “Buy” according to the report published on December 01st, 2022.
H.C. Wainwright gave a rating of “Buy” to SWTX, setting the target price at $101 in the report published on January 19th of the previous year.
SWTX Trading at -10.27% from the 50-Day Moving Average
After a stumble in the market that brought SWTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.62% of loss for the given period.
Volatility was left at 6.12%, however, over the last 30 days, the volatility rate increased by 7.44%, as shares sank -3.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.84% lower at present.
During the last 5 trading sessions, SWTX fell by -9.78%, which changed the moving average for the period of 200-days by +46.33% in comparison to the 20-day moving average, which settled at $44.11. In addition, SpringWorks Therapeutics Inc saw 15.78% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SWTX starting from Pichl Daniel, who sale 15,000 shares at the price of $50.10 back on Feb 16 ’24. After this action, Pichl Daniel now owns 45,212 shares of SpringWorks Therapeutics Inc, valued at $751,550 using the latest closing price.
Ashar Bhavesh, the Chief Commercial Officer of SpringWorks Therapeutics Inc, sale 4,834 shares at $49.32 during a trade that took place back on Feb 05 ’24, which means that Ashar Bhavesh is holding 58,154 shares at $238,435 based on the most recent closing price.
Stock Fundamentals for SWTX
Current profitability levels for the company are sitting at:
- -9.49 for the present operating margin
- 0.88 for the gross margin
The net margin for SpringWorks Therapeutics Inc stands at -8.95. The total capital return value is set at -0.61. Equity return is now at value -63.12, with -55.31 for asset returns.
Based on SpringWorks Therapeutics Inc (SWTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -36.56. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -83.96.
Currently, EBITDA for the company is -341.35 million with net debt to EBITDA at 0.31. When we switch over and look at the enterprise to sales, we see a ratio of 79.74. The receivables turnover for the company is 2.44for trailing twelve months and the total asset turnover is 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.85.
Conclusion
In summary, SpringWorks Therapeutics Inc (SWTX) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
